Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Executive Editor
Washington DC, USA
+16 year(s) experience
Bowman has followed various energy, environmental and health care sectors, writing news for pharmacists, chemists, engineers, lawyers and other professionals.He has moderated and presented at industry and journalism conferences, and has a background in product development, having helped launch publications, conferences and a journalism association.
Bowman has a passion for connecting with professional communities, discovering their truths, telling their stories and helping them learn from each other. Other passions: crowd sourcing, data mining, classic movies and working on his basketball game.
Pink Sheet
Just as they did during the heparin crisis a decade ago, pharmaceutical companies must coordinate on coronavirus, Rx-360 CEO says.
Topic Manufacturing Vaccines Coronavirus
Scrip
As coronavirus spreads into China’s manufacturing region, quarantines and travel restrictions challenge international flow of pharmaceuticals, ingredients and personnel.
Topic Coronavirus
Pink Sheet
When firms are developing highly anticipated gene therapies, it’s important to establish GMP-controlled manufacturing processes earlier in development, as Sarepta discovered when US FDA placed a clinical hold on a promising Duchenne muscular dystrophy gene therapy.
Topic FDA
Scrip
An FDA warning letter to a contract manufacturer, Pfizer, delayed Sandoz/Momenta's Glatopa 40 mg launch, reducing projected revenues and leading Momenta to consider selling assets.
Topic FDA Business strategies
Pink Sheet
The race is on in Puerto Rico to avert critical drug shortages that could hit the US in a few months if service from the island's electrical grid hasn't been restored.
Topic BioPharmaceutical
Pink Sheet
Congressional oversight agency urges FDA to make better use of foreign offices with more effective performance measures and staffing goals; GAO notes agency’s progress towards risk-based inspections – and its plan to revisit every site at least once every five years.
Pink Sheet
05 May 2021
Pink Sheet
04 May 2021
Pink Sheet
03 May 2021
HBW Insight
03 May 2021
Pink Sheet
22 Apr 2021
Pink Sheet
19 Apr 2021
Pink Sheet
15 Apr 2021
HBW Insight
15 Apr 2021
Pink Sheet
14 Apr 2021
Pink Sheet
11 Apr 2021
Pink Sheet
11 Apr 2021
Pink Sheet
05 Apr 2021
Pink Sheet
31 Mar 2021
Pink Sheet
29 Mar 2021
Pink Sheet
11 Mar 2021
